ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Current Quarter	$0.19	Next Quarter	$0.21
Current Year	$0.64	Next Year	$0.9
QoQ Growth	+10.5%	YoY Growth	+40.6%
3Y EPS CAGR	+54.2%	Target Price	$30.67
Consensus	Buy	Upside	+54.1%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADMA	$19.90	-2.35%	1.40M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADMA	$19.90	-2.3%	1.40M
3
4
5
6

ADMA

ADMA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get ADMA Biologics Inc Data in Excel

Get ADMA Biologics Inc Data in Excel